Your email has been successfully added to our mailing list.

×
0 0 0 0 0.0105112279025324 0.00167224080267559 0.00621118012422372 0.0129001433349259
Stock impact report

Immunomedics files U.S. marketing application for sacituzumab govitecan for TNBC [Seeking Alpha]

IMMUNOMEDICS (IMMU) 
Last immunomedics earnings: 2/27 04:00 pm Check Earnings Report
Company Research Source: Seeking Alpha
Immunomedics files U.S. marketing application for sacituzumab govitecan for TNBCImmunomedics (NASDAQ:IMMU)files a U.S. marketing application seeking approval for antibody-drug conjugate sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior lines of therapy.Previously:Immunomedics' IMMU-132 shows 31% response rate in TNBC; shares ahead 19% (Dec. 6, 2017)Click to subscribe to real-time analytics on IMMUNow read:Biotechs Emerge Unscathed And Ready To Go! » Show less Read more
Impact Snapshot
Event Time:
IMMU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IMMU alerts
Opt-in for
IMMU alerts

from News Quantified
Opt-in for
IMMU alerts

from News Quantified